Cat. #153263
Anti-CD55 [BU14] rAb
Cat. #: 153263
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: CD55 (CD97 ligand)
Class: Recombinant
Application: FACS ; IP
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Jefferis
Institute: Absolute Antibody ; University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-CD55 [BU14] rAb
- Alternate name: CD55 Molecule (Cromer Blood Group); CD55 Molecule; Decay Accelerating Factor For Complement (Cromer Blood Group); CD55 Antigen; DAF; CR; Decay Accelerating Factor For Complement; CROM; TC
- Clone: BU14
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IP
- Description: CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours.
- Isotype: IgG1
Target Details
- Target: CD55 (CD97 ligand)
- Target background: CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours.
Applications
- Application: FACS ; IP
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS
- Shipping conditions: Shipping at 4° C
References
- Original hybridoma first published in: Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.
